Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Unable to raise venture money when it spun out of service play Epitomics Inc. in 2010, Apexigen Inc. was able to work for three years using $2 million in seed funding plus partnership
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury